Table 1.
Baseline Demographic characteristics and laboratory values in R/R CLL patients with Ibrutinib monotherapy
| CLL patients with secondary hypogammaglobulinemia | CLL patients without secondary hypogammaglobulinemia | p | |
|---|---|---|---|
| Age (years) | 61.1 ± 9.8 | 63.06 ± 9.2 | 0.62t |
| WBC (103/µL) | 24 (11.9–87) | 31.8 (2.7–262) | 0.38 m |
| Lym (103/µL) | 19.9 (7.9–80) | 24.2 (2–243) | 0.38 m |
| Neu (103/µL) | 3.9 (1.5–7.1) | 4.65 (0.6–25.4) | 0.72 m |
| Hb (g/dL) | 12.8 ± 2.2 | 11.3 ± 2.4 | 0.14 t |
| PLT (103/µL) | 146.6 ± 53.1 | 215.7 ± 80.1 | 0.03t |
| LDH(u/L) | 297 (154–810) | 248.5 (179–767) | 0.43 m |
| Β2MG (mg/dL) | 0.53 (0.42–3.94) | 0.55 (0.24–1.57) | 0.57 m |
| IgG (mg/dL) | 830.2 ± 194 | 1304 ± 425 | 0.004t |
| Follow up time (months) | 77 ( 28–120) | 33.5 (16–131) | 0.05m |
Bold values indicate the p value 0.05 and below is significant
Β2MG, beta 2 microglobulin Hb, hemoglobulin; IgG, immunoglobulin G; LDH, lactate dehydrogenase; Lym, lymphocyte; Neu, neutrophil; PLT, platelet; WBC, white blood cell
mMann-Whitney U, tIndependent Samples T test